A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
This research study is investigating an experimental drug named Nipocalimab for adults who have idiopathic inflammatory myopathies (IIM), also known as myositis. These conditions cause muscle weakness and inflammation. The main goal is to find out if Nipocalimab is effective and safe compared to a placebo (a dummy treatment). Participants will also be receiving standard treatments like glucocorticoids. By comparing the new drug to a placebo, researchers hope to understand if Nipocalimab could be a helpful new option for managing the symptoms of active IIM. It's a 'Phase 2' study, meaning it's still in the earlier stages of testing.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is designed to explore a new treatment called Nipocalimab for people who have a group of conditions known as idiopathic inflammatory myopathies (IIMs), or myositis. These are conditions where your body's immune system mistakenly attacks your muscles (and sometimes other parts of the body), leading to weakness, pain, and inflammation. The aim is to see if Nipocalimab can help improve symptoms and is safe to use in people whose condition is currently active.
You might be wondering what Nipocalimab is. It's an experimental drug, which means it's still being tested and isn't yet available as a standard treatment. In this study, some people will receive Nipocalimab, while others will receive a placebo – which looks exactly like the study drug but contains no active medicine. This is a common way to accurately test if a new drug works better than no treatment at all. All participants will also continue with their usual care, which may include steroid medications (glucocorticoids).
This is a 'Phase 2' study. This means it's an important step in developing new medicines. Researchers are looking for early signs of how well the drug works and checking its safety in a larger group of people than in a Phase 1 study. The findings from this study will help decide if Nipocalimab should be studied further in even larger trials.
النقاط الرئيسية
- This study is for adults with active inflammatory myopathies (myositis).
- It's testing a new medication called Nipocalimab against a dummy treatment (placebo).
- You'll continue your existing steroid medications (glucocorticoids) if prescribed.
- The study involves regular clinic visits for assessments and monitoring.
- Your myositis diagnosis will be confirmed using specific criteria, including blood antibody tests.
من قد يكون مؤهلاً؟
To join this study, you must be an adult aged 18 or over. You need to have been diagnosed with an idiopathic inflammatory myopathy (IIM), or myositis, for at least six weeks before the study starts, and your condition must be active. Doctors will use specific guidelines to confirm your diagnosis.
An important part of eligibility is having certain 'myositis-specific' antibodies in your blood. These antibodies help doctors understand the specific type of myositis you have. You'll have blood tests to check for these antibodies. If you're using certain skin creams for your condition, such as mild steroid creams or tacrolimus, the dose needs to have been stable for at least four weeks before starting the study and kept the same throughout most of the study.
There are also reasons why you might not be able to join. For example, if you were diagnosed with myositis when you were a child and are now an adult, you wouldn't be eligible. Also, if you have myositis linked to cancer, you wouldn't be able to take part in this particular study.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- هل عمرك 18 سنة أو أكثر؟
- Have you been diagnosed with inflammatory myopathy (myositis) for at least six weeks, and is your condition currently active?
- Have your doctors identified specific 'myositis-specific' antibodies in your blood?
- If you use skin creams for myositis, has the dose been stable for at least four weeks?
- Have you *not* been diagnosed with juvenile myositis (myositis diagnosed in childhood)?
ماذا يتضمن المشاركة؟
The study involves several visits to the clinic over a period of time. You will be assigned to either receive the study drug (Nipocalimab) or a placebo, and you won't know which one you're getting. You'll also continue to receive any steroid medications (glucocorticoids) your doctor has prescribed for your condition. During your visits, the research team will perform various assessments, including blood tests, physical examinations, and asking you questions about how you're feeling and how your symptoms are changing. These assessments help the researchers understand how the study drug affects your condition and to monitor your health. The total duration of your participation in the study, including follow-up, will be determined by the study design, potentially up to 52 weeks.
المخاطر والفوائد المحتملة
المواقع (57)
- Arizona Arthritis and Rheumatology Research PLLCالرمز البريدي المؤكدفينيكس، الولايات المتحدة
- HonorHealth Neurologyالرمز البريدي المؤكدسكوتسديل، الولايات المتحدة
- Attune Health Autoimmune and Inflamation Care and Researchالرمز البريدي المؤكدبيفرلي هيلز، الولايات المتحدة
- University of California Irvine Medical Centerالرمز البريدي المؤكدأورانج، الولايات المتحدة
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Centerالرمز البريدي المؤكدتورانس، الولايات المتحدة
- FM Clinical Research, LLC South Florida Neurology Associates, P. A.الرمز البريدي المؤكدبوكا راتون، الولايات المتحدة
- Integral Rheumatology And Immunology Specialistsالرمز البريدي المؤكدبلانتيشن، الولايات المتحدة
- جامعة جنوب فلوريداالرمز البريدي المؤكدتامبا، الولايات المتحدة
- جامعة أوغوستاالرمز البريدي المؤكدأوغوستا، الولايات المتحدة
- مركز جامعة كانساس الطبيالرمز البريدي المؤكدكانساس سيتي، الولايات المتحدة
- Johns Hopkins Universityالرمز البريدي المؤكدبالتيمور، الولايات المتحدة
- The Brigham and Women's Hospital, Inc.الرمز البريدي المؤكدبوسطن، الولايات المتحدة
أسئلة شائعة
ما هو التهاب العضلات؟
Myositis is a group of conditions where your body's immune system mistakenly attacks your muscles, causing weakness and inflammation.
What is Nipocalimab?
Nipocalimab is an experimental medication being tested to see if it can help people with inflammatory myopathies. It's not yet available as a standard treatment.
ما هو الدواء الوهمي؟
A placebo is a 'dummy' treatment that looks just like the real study drug but contains no active medicine. It helps researchers compare the effects of the new drug.
Will I still take my regular medicines?
Yes, you will continue with your usual treatments for myositis, such as steroid medications, alongside the study drug or placebo.
هل يمكنني مغادرة الدراسة إذا غيرت رأيي؟
Absolutely. You are free to withdraw from the study at any time, for any reason, without it affecting your regular medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.